AGMB (AgomAb Therapeutics NV) Change In Receivables: $0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AGMB AgomAb Therapeutics NV AGMB
14 GF Score
Price $14.30
! 1 Warning Sign
View Full Analysis

What is AgomAb Therapeutics NV Change In Receivables?

AgomAb Therapeutics NV AGMB +1.96% 14 Change In Receivables is $0.00 Mil as of Jun. 2026. GuruFocus rates AGMB with a GF Score™ of 14/100. The stock has 1 warning sign investors should review.

AgomAb Therapeutics NV's change in receivables for the quarter that ended in Jun. 2026 was $0.00 Mil. It means AgomAb Therapeutics NV's Accounts Receivable stayed the same from Dec. 2025 to Jun. 2026 .

AgomAb Therapeutics NV's change in receivables for the fiscal year that ended in Dec. 2025 was $0.00 Mil. It means AgomAb Therapeutics NV's Accounts Receivable stayed the same from Dec. 2024 to Dec. 2025 .

AgomAb Therapeutics NV's Accounts Receivable for the quarter that ended in Jun. 2026 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. AgomAb Therapeutics NV's liquidation value for the three months ended in Jun. 2026 was $260.86 Mil.

AgomAb Therapeutics NV  (NAS:AGMB) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

AgomAb Therapeutics NV's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/0*91
=

2. In Ben Graham's calculation of liquidation value, AgomAb Therapeutics NV's accounts receivable are only considered to be worth 75% of book value:

AgomAb Therapeutics NV's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=290.296-29.432+0.75 * 0+0.5 * 0
=260.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AgomAb Therapeutics NV Change In Receivables Related Terms

AgomAb Therapeutics NV Change In Receivables Historical Data

* Premium members only.

The historical data trend for AgomAb Therapeutics NV's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AgomAb Therapeutics NV Change In Receivables Chart

AgomAb Therapeutics NV Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
0.00 0.00 0.00 0.00 0.00

AgomAb Therapeutics NV Quarterly Data
Dec21 Dec22 Dec23 Dec24 Sep25 Dec25 Jun26
Change In Receivables Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
AGMB
14GF Score
AgomAb Therapeutics NV AGMB
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AgomAb Therapeutics NV Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $0.00 Mil mean?
AgomAb Therapeutics NV (AGMB) has a Change In Receivables of $0.00 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for AgomAb Therapeutics NV and its competitors.
Is AgomAb Therapeutics NV's Change In Receivables too high?
AgomAb Therapeutics NV's current Change In Receivables is $0.00 Mil. Overall, AgomAb Therapeutics NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does AgomAb Therapeutics NV's Change In Receivables compare to CRMD and RGNX?
AgomAb Therapeutics NV's Change In Receivables of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for AgomAb Therapeutics NV and its competitors. AgomAb Therapeutics NV's current Change In Receivables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AgomAb Therapeutics NV stock overvalued right now?
AgomAb Therapeutics NV (AGMB) has a current Change In Receivables of $0.00 Mil. The current Change In Receivables is $0.00 Mil. AgomAb Therapeutics NV's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For AgomAb Therapeutics NV (AGMB), the current Change In Receivables is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AgomAb Therapeutics NV Business Description

Address 1/6 Posthoflei, Antwerp, BEL, 2600
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
14GF Score

Get the complete analysis for AGMB

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.30
Price